Cardinal Health, Inc. logo

Cardinal Health, Inc.

CAH

NYSEHealthcareMedical - Distribution

Latest quote

$235.27

+$2.82 · +1.21%

Aug 25, 1:15 PM ET

CAH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

42

Fair Value

Momentum

58

Neutral

Sentiment

62

Bullish

Risk resilience

87

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
US
CEO
Jason Hollar
Listed since
Aug 4, 1983
Employees
61,344

Market position

Volume
504.15K
0.22× average
Average volume
2.26M
Average daily volume
Market cap
55.08B USD
Beta
0.52
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
61.16B USD
P/E (TTM)
32.35×
P/B (TTM)
-19.25×
P/S (TTM)
0.22×
EV / EBITDA
17.58×
Earnings yield
3.06%
Free cash flow yield
8.07%
Dividend yield
0.87%

Profitability & efficiency

Gross margin
3.84%
Operating margin
1.03%
Net margin
0.67%
Return on equity
-59.45%
Return on assets
2.99%
Return on invested capital
13.24%

Financial health

Debt / equity
-3.45×
Current ratio
0.88×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends4%3%1%-1%Gross margin, FY2022: 3.58%Gross margin, FY2023: 3.36%Gross margin, FY2024: 3.27%Gross margin, FY2025: 3.67%Gross margin, FY2026: 3.84%Operating margin, FY2022: -0.33%Operating margin, FY2023: 0.37%Operating margin, FY2024: 0.55%Operating margin, FY2025: 1.02%Operating margin, FY2026: 1.03%Net margin, FY2022: -0.52%Net margin, FY2023: 0.16%Net margin, FY2024: 0.38%Net margin, FY2025: 0.70%Net margin, FY2026: 0.67%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 3.58%. Gross margin FY2023 3.36%. Gross margin FY2024 3.27%. Gross margin FY2025 3.67%. Gross margin FY2026 3.84%. Operating margin FY2022 -0.33%. Operating margin FY2023 0.37%. Operating margin FY2024 0.55%. Operating margin FY2025 1.02%. Operating margin FY2026 1.03%. Net margin FY2022 -0.52%. Net margin FY2023 0.16%. Net margin FY2024 0.38%. Net margin FY2025 0.70%. Net margin FY2026 0.67%.

Income trends

Revenue

254.25B USD+14.23%

Operating income

2.61B USD+14.86%

Net income

1.71B USD+9.80%
Income trends across reported periods279.77B USD177.69B USD75.62B USD−26.46B USDRevenue, FY2022: 181.33B USDRevenue, FY2023: 204.98B USDRevenue, FY2024: 226.83B USDRevenue, FY2025: 222.58B USDRevenue, FY2026: 254.25B USDOperating income, FY2022: −607M USDOperating income, FY2023: 752M USDOperating income, FY2024: 1.24B USDOperating income, FY2025: 2.28B USDOperating income, FY2026: 2.61B USDNet income, FY2022: −938M USDNet income, FY2023: 330M USDNet income, FY2024: 852M USDNet income, FY2025: 1.56B USDNet income, FY2026: 1.71B USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 181.33B USD. Revenue FY2023 204.98B USD. Revenue FY2024 226.83B USD. Revenue FY2025 222.58B USD. Revenue FY2026 254.25B USD. Operating income FY2022 −607M USD. Operating income FY2023 752M USD. Operating income FY2024 1.24B USD. Operating income FY2025 2.28B USD. Operating income FY2026 2.61B USD. Net income FY2022 −938M USD. Net income FY2023 330M USD. Net income FY2024 852M USD. Net income FY2025 1.56B USD. Net income FY2026 1.71B USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue254.25B USD222.58B USD226.83B USD204.98B USD181.33B USD
Cost of goods sold244.47B USD214.41B USD219.41B USD198.11B USD174.84B USD
Gross profit9.77B USD8.17B USD7.41B USD6.89B USD6.48B USD
Selling, general, and administrative6.13B USD5.38B USD5B USD4.8B USD4.51B USD
Operating expenses7.16B USD5.89B USD6.17B USD6.12B USD7.09B USD
Interest expense348M USD215M USD51M USD84M USD147M USD
Depreciation and amortization956M USD790M USD710M USD692M USD692M USD
Operating income2.61B USD2.28B USD1.24B USD752M USD−607M USD
Net income1.71B USD1.56B USD852M USD330M USD−938M USD

Company facts updated Aug 25, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$273.22

16.17% upside
Past 12 months12-month forecastHigh $292Average $273.22Low $250

Corporate actions

Corporate action history

Stock split

Effective Apr 23, 2001

3:2

Stock split

Effective Nov 2, 1998

3:2

Stock split

Effective Dec 17, 1996

3:2

Stock split

Effective Jul 1, 1994

5:4

Stock split

Effective Oct 1, 1991

5:4

Stock split

Effective Oct 1, 1990

5:4

CAH peers

ETFs holding CAH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CAH

research.disclaimer